www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2713

Title: Effect of risedronate on the risk of hip fracture in elderly women
Authors: McClung, Michael
Miller, Paul D.
Zippel, H
Bensen, W.G.
Roux, C
Adami, S.
Fogelman, I
Diamond, T
Eastell, R
Meunier, P.J.
Reginster, JY
Wasnich, RD
Greenwald, M
Kaufman, J
Chestnut, CH
GEUSENS, Piet
Issue Date: 2001
Publisher: MASSACHUSETTS MEDICAL SOC
Citation: NEW ENGLAND JOURNAL OF MEDICINE, 344(5). p. 333-340
Abstract: Background: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. Methods: We studied 5445 women 70 to 79 years old who had osteoporosis (indicated by a T score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak value in young adults [-4] or lower than -3 plus a nonskeletal risk factor for hip fracture, such as poor gait or a propensity to fall) and 3886 women at least 80 years old who had at least one nonskeletal risk factor for hip fracture or low bone mineral density at the femoral neck (T score, lower than -4 or lower than -3 plus a hip-axis length of 11.1 cm or greater). The women were randomly assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three years. The primary end point was the occurrence of hip fracture. Results: Overall, the incidence of hip fracture among all the women assigned to risedronate was 2.8 percent, as compared with 3.9 percent among those assigned to placebo (relative risk, 0.7; 95 percent confidence interval, 0.6 to 0.9; P=0.02). In the group of women with osteoporosis (those 70 to 79 years old), the incidence of hip fracture among those assigned to risedronate was 1.9 percent, as compared with 3.2 percent among those assigned to placebo (relative risk, 0.6; 95 percent confidence interval, 0.4 to 0.9; P=0.009). In the group of women selected primarily on the basis of nonskeletal risk factors (those at least 80 years of age), the incidence of hip fracture was 4.2 percent among those assigned to risedronate and 5.1 percent among those assigned to placebo (P=0.35). Conclusions: Risedronate significantly reduces the risk of hip fracture among elderly women with confirmed osteoporosis but not among elderly women selected primarily on the basis of risk factors other than low bone mineral density. (N Engl J Med 2001;344:333-40.) Copyright (C) 2001 Massachusetts Medical Society.
Notes: Oregon Osteoporosis Ctr, Portland, OR 97213 USA. Providence Med Ctr, Portland, OR USA. Limburgs Univ Ctr, Diepenbeek, Belgium. Univ Maastricht, Maastricht, Netherlands. Colorado Ctr Bone Res, Lakewood, CO USA. Humboldt Univ, Charite, Berlin, Germany. McMaster Univ, St Josephs Hosp, Hamilton, ON, Canada. Hop Cochin, F-75674 Paris, France. Ctr Osped, Clin Valeggio, Valeggio, Italy. Guys Hosp, London SE1 9RT, England. St George Hosp, Kogarah, NSW 2217, Australia. Univ Sheffield, Sheffield, S Yorkshire, England. Hop Edouard Herriot, Lyon, France. Univ Liege, Liege, Belgium.McClung, MR, Oregon Osteoporosis Ctr, 5050 NE Hoyt,Suite 651, Portland, OR 97213 USA.
URI: http://hdl.handle.net/1942/2713
ISI #: 000166675800003
ISSN: 0028-4793
Category: A1
Type: Journal Contribution
Validation: ecoom, 2002
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.